Details

Last Funding Type

Debt Financing

Last Funding Money Raised

€25M

Industries

Biotechnology,Health Care,Life Science,Therapeutics

Founded date

Jan 1, 2020

Number Of Employee

1 - 10

Operating Status

Active

ExeVir Bio is a Belgium-based company that develops single-domain antibody-based therapies that help patients ward off viral infections. The company is harnessing a llama-derived antibody technology platform to generate robust antiviral therapies providing broad protection against coronaviruses. They using a highly innovative and clinically validated VHH technology to develop treatments for viral infections that may pose a significant global threat.

ExeVir Bio develops a rapid response platform for antivirals. This platform technology enables an agile response to new health threats thanks to its short throughput time to generate drug candidates. The resulting protein-based therapeutics are sufficiently stable and easy to produce at a reasonable cost to enable true global access.

ExeVir Bio was founded in 2020 and is headquartered in Zwijnaarde, Belgium.